Semaglutide is a glucagon-like peptide-1 analogue with two amino acid substitutions (Aib8, Arg34) and a fatty-acid derivatization at lysine 26, designed for high albumin affinity and once-weekly dosing.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 3 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
Semaglutide is a glucagon-like peptide-1 analogue with two amino acid substitutions (Aib8, Arg34) and a fatty-acid derivatization at lysine 26, designed for high albumin affinity and once-weekly dosing. · pmid:26308095
History
In SUSTAIN-6, 3,297 patients with type 2 diabetes had fewer cardiovascular deaths, non-fatal heart attacks or non-fatal strokes on semaglutide than on placebo (6.6% against 8.9%; hazard ratio 0.74). · pmid:27633186
In the 68-week STEP 1 trial of 1,961 adults with overweight or obesity, mean body weight fell by 14.9% on semaglutide 2.4 mg weekly against 2.4% on placebo. · pmid:33567185
Proportion of the 3 claims about Semaglutide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
3 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Semaglutide yet.
Dose evidence, rung by rung
A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. · pmid 27633186 · 2016
Once-Weekly Semaglutide in Adults with Overweight or Obesity. · pmid 33567185 · 2021
Observational evidence· resolved human data at the emerging tier: thin, or contested
nothing resolved on this rung
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. · pmid 26308095 · 2015
3 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.